<DOC>
	<DOCNO>NCT00116753</DOCNO>
	<brief_summary>The rationale study evaluate different degarelix dose regimen three-month interval produce maintain castration prostate cancer patient immediate prolonged testosterone suppression , provide confirmatory evidence safety degarelix .</brief_summary>
	<brief_title>A Comparative Study Degarelix Three-month Depot Three Different Dosing Regimens Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has give write consent studyrelated activity perform . A studyrelated activity define procedure would perform normal management patient . Has histologically confirm ( Gleason grade ) adenocarcinoma prostate ( stage ) endocrine treatment , except neoadjuvant hormonal therapy , indicate . This include patient rise PSA undergone prostatectomy radiotherapy curative intention . Is male patient age 18 year . Has baseline serum testosterone level lower limit normal range , globally define &gt; 2.2 ng/mL . Has ECOG ( Eastern Cooperative Oncology Group ) score 2 . Has PSA value 2 ng/mL . Has life expectancy least 13 month . Has previous currently hormonal management prostate cancer ( surgical castration hormonal manipulation , e.g . GnRH agonist , GnRH antagonists , antiandrogens , oestrogen ) . However , patient undergone prostatectomy radiotherapy curative intention , neoadjuvant hormonal therapy accept maximal duration 6 month . This treatment terminate least 6 month prior Screening Visit . Is consider candidate curative therapy , i.e . radical prostatectomy radiotherapy within 13 month Screening Visit . Has history , predisposition , severe hypersensitivity reaction severe asthma ( defined need daily treatment inhalation steroid control asthma ) , anaphylactic reaction , chronic recurrent urticaria and/or angioedema . Has hypersensitivity towards component investigational medicinal product . 5 . Has cancer disease within last five year except prostate cancer surgically remove basal squamous cell carcinoma skin . Has know suspect hepatic symptomatic biliary disease . Has elevate serum ALT level upper level normal range serum total bilirubin level upper level normal range measure laboratory Screening Visit . Has clinically significant laboratory abnormality , judgment investigator would interfere patient 's participation study evaluation study result . Has clinically significant disorder ( prostate cancer ) condition , include excessive alcohol drug abuse , may interfere study participation may affect conclusion study judge investigator . Has mental incapacity language barrier preclude adequate understanding cooperation . Has receive investigational drug within last 28 day precede Screening Visit longer consider investigator possibly influence outcome current study . Has previously participate degarelix study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>